Jon Bruss

2.5k total citations
33 papers, 1.9k citations indexed

About

Jon Bruss is a scholar working on Infectious Diseases, Pharmacology and Epidemiology. According to data from OpenAlex, Jon Bruss has authored 33 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 10 papers in Pharmacology and 10 papers in Epidemiology. Recurrent topics in Jon Bruss's work include Antimicrobial Resistance in Staphylococcus (15 papers), Bacterial Identification and Susceptibility Testing (10 papers) and Antibiotics Pharmacokinetics and Efficacy (10 papers). Jon Bruss is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (15 papers), Bacterial Identification and Susceptibility Testing (10 papers) and Antibiotics Pharmacokinetics and Efficacy (10 papers). Jon Bruss collaborates with scholars based in United States, Saudi Arabia and Kazakhstan. Jon Bruss's co-authors include Sheldon L. Kaplan, SHARON NABERHUIS-STEHOUWER, A. C. R. Tanner, Chris Riedy, Peter Milgrom, Vu Le, Philip Weinstein, Stanton L. Gerson, Barry Hafkin and David J. Kuter and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Infection and Immunity.

In The Last Decade

Jon Bruss

33 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jon Bruss United States 22 918 471 434 431 396 33 1.9k
María-José Giménez Spain 26 549 0.6× 172 0.4× 667 1.5× 1.3k 3.0× 265 0.7× 189 2.4k
J. Caillon France 32 958 1.0× 451 1.0× 689 1.6× 1.0k 2.3× 351 0.9× 192 3.4k
E. J. C. Goldstein United States 22 807 0.9× 245 0.5× 242 0.6× 560 1.3× 601 1.5× 43 1.9k
Yuka Yamagishi Japan 24 752 0.8× 263 0.6× 291 0.7× 871 2.0× 235 0.6× 213 2.3k
Fu‐Der Wang Taiwan 29 895 1.0× 276 0.6× 301 0.7× 766 1.8× 166 0.4× 112 2.5k
Murray A. Abramson United States 17 459 0.5× 295 0.6× 218 0.5× 384 0.9× 372 0.9× 27 1.9k
Paula Ramírez Spain 30 868 0.9× 218 0.5× 305 0.7× 1.7k 3.9× 199 0.5× 121 3.0k
Mark LaRocco United States 23 606 0.7× 187 0.4× 189 0.4× 770 1.8× 120 0.3× 61 1.9k
Kenneth J. Tack United States 24 684 0.7× 358 0.8× 490 1.1× 622 1.4× 294 0.7× 45 1.6k
B. Oppenheim United Kingdom 25 522 0.6× 258 0.5× 134 0.3× 410 1.0× 144 0.4× 50 1.5k

Countries citing papers authored by Jon Bruss

Since Specialization
Citations

This map shows the geographic impact of Jon Bruss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Bruss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Bruss more than expected).

Fields of papers citing papers by Jon Bruss

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Bruss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Bruss. The network helps show where Jon Bruss may publish in the future.

Co-authorship network of co-authors of Jon Bruss

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Bruss. A scholar is included among the top collaborators of Jon Bruss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Bruss. Jon Bruss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wilson, Samuel E., et al.. (2017). Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies. Infectious Diseases and Therapy. 6(3). 413–422. 14 indexed citations
2.
Shinabarger, Dean L., et al.. (2017). Evaluation of the bactericidal activity of Telavancin against Staphylococcus aureus using revised testing guidelines. Diagnostic Microbiology and Infectious Disease. 89(1). 83–85. 4 indexed citations
3.
Solomkin, Joseph S., John B. Cone, Samuel E. Wilson, et al.. (2013). Source Control Review in Clinical Trials of Anti-Infective Agents in Complicated Intra-Abdominal Infections. Clinical Infectious Diseases. 56(12). 1765–1773. 36 indexed citations
4.
Cass, Robert, et al.. (2011). Pharmacokinetics and Safety of Single and Multiple Doses of ACHN-490 Injection Administered Intravenously in Healthy Subjects. Antimicrobial Agents and Chemotherapy. 55(12). 5874–5880. 60 indexed citations
5.
Handen, Benjamin L., Raun D. Melmed, Robin Hansen, et al.. (2009). A Double-Blind, Placebo-Controlled Trial of Oral Human Immunoglobulin for Gastrointestinal Dysfunction in Children with Autistic Disorder. Journal of Autism and Developmental Disorders. 39(5). 796–805. 31 indexed citations
6.
Milne, Christopher‐Paul & Jon Bruss. (2008). The economics of pediatric formulation development for off-patent drugs. Clinical Therapeutics. 30(11). 2133–2145. 81 indexed citations
7.
Yogev, Ram, L. E. R. Patterson, Sheldon L. Kaplan, et al.. (2003). Linezolid for the treatment of complicated skin and skin structure infections in children. The Pediatric Infectious Disease Journal. 22(9). S172–S177. 42 indexed citations
8.
Meissner, H. Cody, Timothy R. Townsend, Wanda M. Wenman, et al.. (2003). Hematologic effects of linezolid in young children. The Pediatric Infectious Disease Journal. 22(9). S186–S192. 56 indexed citations
9.
Kaplan, Sheldon L., Jaime G. Deville, Ram Yogev, et al.. (2003). Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. The Pediatric Infectious Disease Journal. 22(8). 677–686. 138 indexed citations
10.
Jantausch, Barbara, Jaime G. Deville, Stuart P. Adler, et al.. (2003). Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens. The Pediatric Infectious Disease Journal. 22(9). S164–S171. 53 indexed citations
11.
Deville, Jaime G., Stuart P. Adler, Parvin H. Azimi, et al.. (2003). Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates. The Pediatric Infectious Disease Journal. 22(9). S158–S163. 76 indexed citations
12.
Saiman, Lisa, et al.. (2003). Safety and tolerability of linezolid in children. The Pediatric Infectious Disease Journal. 22(9). S193–S200. 59 indexed citations
13.
Tregnaghi, Miguel, et al.. (2003). Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. The Pediatric Infectious Disease Journal. 22(4). 315–322. 48 indexed citations
14.
Wilson, Samuel E., Joseph S. Solomkin, Vu Le, Sue Cammarata, & Jon Bruss. (2003). A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. The American Journal of Surgery. 185(4). 369–375. 33 indexed citations
15.
Kaplan, Sheldon L., Behnoosh Afghani, Pío López, et al.. (2003). Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. The Pediatric Infectious Disease Journal. 22(9). S178–S185. 56 indexed citations
16.
Tanner, A. C. R., Peter Milgrom, Sameer A. Mokeem, et al.. (2002). Periodontal pathogen detection in gingiva/tooth and tongue flora samples from 18‐ to 48‐month‐old children and periodontal status of their mothers. Oral Microbiology and Immunology. 17(1). 55–59. 37 indexed citations
17.
Tanner, A. C. R., Peter Milgrom, Ralph Kent, et al.. (2002). Similarity of the oral microbiota of pre‐school children with that of their caregivers in a population‐based study. Oral Microbiology and Immunology. 17(6). 379–387. 48 indexed citations
18.
Gerson, Stanton L., Sheldon L. Kaplan, Jon Bruss, et al.. (2002). Hematologic Effects of Linezolid: Summary of Clinical Experience. Antimicrobial Agents and Chemotherapy. 46(8). 2723–2726. 332 indexed citations
19.
Tanner, A. C. R., Peter Milgrom, Ralph Kent, et al.. (2002). The Microbiota of Young Children from Tooth and Tongue Samples. Journal of Dental Research. 81(1). 53–57. 136 indexed citations
20.
Milgrom, Peter, et al.. (2000). Dental caries and its relationship to bacterial infection, hypoplasia, diet, and oral hygiene in 6‐ to 36‐month‐old children. Community Dentistry And Oral Epidemiology. 28(4). 295–306. 183 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by María-José Giménez Breakdown of academic impact, for papers by J. Caillon Breakdown of academic impact, for papers by E. J. C. Goldstein Breakdown of academic impact, for papers by Yuka Yamagishi Breakdown of academic impact, for papers by Fu‐Der Wang Breakdown of academic impact, for papers by Murray A. Abramson Breakdown of academic impact, for papers by Paula Ramírez Breakdown of academic impact, for papers by Mark LaRocco Breakdown of academic impact, for papers by Kenneth J. Tack Breakdown of academic impact, for papers by B. Oppenheim
Rankless by CCL
2026